AXQ Capital LP Takes Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

AXQ Capital LP bought a new stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 13,154 shares of the company’s stock, valued at approximately $29,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of VTYX. Sio Capital Management LLC increased its stake in Ventyx Biosciences by 153.2% in the third quarter. Sio Capital Management LLC now owns 1,971,948 shares of the company’s stock valued at $4,299,000 after purchasing an additional 1,193,024 shares during the period. Vestal Point Capital LP increased its position in Ventyx Biosciences by 31.2% in the 3rd quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock valued at $3,760,000 after acquiring an additional 410,000 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its stake in Ventyx Biosciences by 88.6% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 871,527 shares of the company’s stock valued at $1,909,000 after acquiring an additional 409,357 shares during the last quarter. Monaco Asset Management SAM acquired a new stake in Ventyx Biosciences during the 4th quarter worth approximately $526,000. Finally, XTX Topco Ltd purchased a new position in shares of Ventyx Biosciences in the 3rd quarter valued at approximately $246,000. Hedge funds and other institutional investors own 97.88% of the company’s stock.

Ventyx Biosciences Trading Up 3.0 %

Shares of VTYX opened at $1.36 on Tuesday. The firm has a market capitalization of $96.74 million, a PE ratio of -0.58 and a beta of 0.58. The stock’s 50 day moving average is $1.70 and its two-hundred day moving average is $2.07. Ventyx Biosciences, Inc. has a twelve month low of $1.28 and a twelve month high of $7.01.

Ventyx Biosciences (NASDAQ:VTYX) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.13. On average, sell-side analysts predict that Ventyx Biosciences, Inc. will post -2.09 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Ventyx Biosciences in a report on Tuesday, January 14th.

Insider Transactions at Ventyx Biosciences

In other news, insider John Nuss sold 21,119 shares of the business’s stock in a transaction that occurred on Friday, December 27th. The stock was sold at an average price of $2.36, for a total transaction of $49,840.84. Following the sale, the insider now owns 464,582 shares of the company’s stock, valued at $1,096,413.52. The trade was a 4.35 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 18.18% of the company’s stock.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.